Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Фармакотерапия хронической обструктивной болезни легких с позиций современных клинических рекомендаций - Справочник поликлинического врача №2 (2015)
Фармакотерапия хронической обструктивной болезни легких с позиций современных клинических рекомендаций
А.А.Зайцев, А.В.Безлепко. Фармакотерапия
хронической обструктивной болезни легких с позиций современных
клинических рекомендаций. Справочник поликлинического врача. 2015; 2: 17–21.
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
Полный текст
Список литературы
1. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2011. Available from: http://www.goldcopd.org/
2. Чучалин А.Г., Айсанов З.Р., Авдеев С.Н. и др. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. М., 2014. http://www.pulmonology.ru/publications/guide.php?clear_cache=Y
3. Roche N, Huchon G. Epidemiology of chronic obstructive pulmonary disease. Rev Prat 2004; 54 (13): 1408–13.
4. World Health Report 2000. Health systems: improving performance. Annex table 3. 2000 World Health Organization. Geneva, Switzerland.
5. Lopez A, Murray C. The global burden of disease 1990–2020. Nat Med 1998; 4: 1241–3.
6. Nakamura M, Oshima A, Fujimoto Y et al. Efficacy and tolerability of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007; 29 (6): 1040–56.
7. Авдеев С.Н. Устройства доставки ингаляционных препаратов, используемые при терапии заболеваний дыхательных путей. Рус. мед. журн. 2002; 5 (10): 255–61.
8. Авдеев С.Н. Хроническая обструктивная болезнь легких. Карманное руководство для практических врачей. М.: Атмосфера, 2010.
9. Tashkin D, Fabbri L. Long_acting beta_agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010; 11: 149.
10. Donohue J, Fogarty C, Lotvall J et al. Once_daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182: 155–62.
11. Kornmann O, Dahl R, Centanni S et al. Once daily indacaterol versus twice_daily salmeterol for COPD: a placebo controlled comparison. European respiratory journal 2011; 37: 273–9.
12. Kerwin et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 study Eur Respir J 2012; 40: 1106–14.
13. D’Urzo et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial Respiratory Research 2011; 12: 156.
14. Cazzola M, Molimard M. The scientific rationale for combining long-acting b2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010; 23: 257–67.
15. Ikeda et al. Regional quantification of muscarinic acetylcholine receptors and b-adrenoceptors in human airway. Br J Pharmacol 2012; 166: 1804–14.
16. Ferguson GT, Anzueto A, Fei R et al. Effect of fluticasone propionate/salmeterol or salmeterol on COPD exacerbations. Respir Med 2008; 102: 1099–108.
17. Kardos P, Wensker M, Glaad T, Vodelmeier C. Impact of salmaterol/fluticasone propionate versus salmoterol on exacerbations in severe CORD. Am J Respir Crit Care Med 2007; 175: 144–9.
18. Сelli B, Calverley P, Anderson J, Ferguson G. The TORCH (Towards a Revolution in CORD Health) study: salmaterol/fluticasone propionate improves health status, reduces exacerbations and improves lung function over three years (abstract). Eur Respir J 2006; 28 (Suppl. 50): 34.
19. Soler-Cataluna J, Martinez-Garcia M, Roman Sanchez P et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925–31.
20. Rabe K. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011; 163: 53–67.
21. Calverley P, Rabe K, Goehring U et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685–94.
22. Decramer M, Rutten-van Molken M, Dekhuijzen PN et al. Effect of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365 (8470): 1552–60.
23. Zheng J, Kang J, Huang S et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008 14; 371 (9629): 2013–8.
24. Wongsurakiat P, Maranetra KN, Wasi C et al. Acute respiratory illness in patients with CORD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004; 125 (6): 2011–20.
25. Furumoto A, Ohkusa Y, Chen M et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008; 26 (33): 4284–9.
2. Чучалин А.Г., Айсанов З.Р., Авдеев С.Н. и др. Федеральные клинические рекомендации по диагностике и лечению хронической обструктивной болезни легких. М., 2014. http://www.pulmonology.ru/publications/guide.php?clear_cache=Y
3. Roche N, Huchon G. Epidemiology of chronic obstructive pulmonary disease. Rev Prat 2004; 54 (13): 1408–13.
4. World Health Report 2000. Health systems: improving performance. Annex table 3. 2000 World Health Organization. Geneva, Switzerland.
5. Lopez A, Murray C. The global burden of disease 1990–2020. Nat Med 1998; 4: 1241–3.
6. Nakamura M, Oshima A, Fujimoto Y et al. Efficacy and tolerability of varenicline, an a4b2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007; 29 (6): 1040–56.
7. Авдеев С.Н. Устройства доставки ингаляционных препаратов, используемые при терапии заболеваний дыхательных путей. Рус. мед. журн. 2002; 5 (10): 255–61.
8. Авдеев С.Н. Хроническая обструктивная болезнь легких. Карманное руководство для практических врачей. М.: Атмосфера, 2010.
9. Tashkin D, Fabbri L. Long_acting beta_agonists in the management of chronic obstructive pulmonary disease: current and future agents. Respir Res 2010; 11: 149.
10. Donohue J, Fogarty C, Lotvall J et al. Once_daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med 2010; 182: 155–62.
11. Kornmann O, Dahl R, Centanni S et al. Once daily indacaterol versus twice_daily salmeterol for COPD: a placebo controlled comparison. European respiratory journal 2011; 37: 273–9.
12. Kerwin et al. Efficacy and safety of NVA237 versus placebo and tiotropium in patients with moderate-to-severe COPD over 52 weeks: The GLOW2 study Eur Respir J 2012; 40: 1106–14.
13. D’Urzo et al. Efficacy and safety of once-daily NVA237 in patients with moderate-to-severe COPD: the GLOW1 trial Respiratory Research 2011; 12: 156.
14. Cazzola M, Molimard M. The scientific rationale for combining long-acting b2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010; 23: 257–67.
15. Ikeda et al. Regional quantification of muscarinic acetylcholine receptors and b-adrenoceptors in human airway. Br J Pharmacol 2012; 166: 1804–14.
16. Ferguson GT, Anzueto A, Fei R et al. Effect of fluticasone propionate/salmeterol or salmeterol on COPD exacerbations. Respir Med 2008; 102: 1099–108.
17. Kardos P, Wensker M, Glaad T, Vodelmeier C. Impact of salmaterol/fluticasone propionate versus salmoterol on exacerbations in severe CORD. Am J Respir Crit Care Med 2007; 175: 144–9.
18. Сelli B, Calverley P, Anderson J, Ferguson G. The TORCH (Towards a Revolution in CORD Health) study: salmaterol/fluticasone propionate improves health status, reduces exacerbations and improves lung function over three years (abstract). Eur Respir J 2006; 28 (Suppl. 50): 34.
19. Soler-Cataluna J, Martinez-Garcia M, Roman Sanchez P et al. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60: 925–31.
20. Rabe K. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol 2011; 163: 53–67.
21. Calverley P, Rabe K, Goehring U et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials. Lancet 2009; 374: 685–94.
22. Decramer M, Rutten-van Molken M, Dekhuijzen PN et al. Effect of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): a randomized placebo-controlled trial. Lancet 2005; 365 (8470): 1552–60.
23. Zheng J, Kang J, Huang S et al. Effect of carbocisteine on acute exacerbation of chronic obstructive pulmonary disease (PEACE Study): a randomised placebo-controlled study. Lancet 2008 14; 371 (9629): 2013–8.
24. Wongsurakiat P, Maranetra KN, Wasi C et al. Acute respiratory illness in patients with CORD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004; 125 (6): 2011–20.
25. Furumoto A, Ohkusa Y, Chen M et al. Additive effect of pneumococcal vaccine and influenza vaccine on acute exacerbation in patients with chronic lung disease. Vaccine 2008; 26 (33): 4284–9.
Авторы
А.А.Зайцев, А.В.Безлепко
ФГКУ Главный военный клинический госпиталь им. акад. Н.Н.Бурденко Минобороны России
ФГКУ Главный военный клинический госпиталь им. акад. Н.Н.Бурденко Минобороны России
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.